Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma

Blood-Brain Barrier Disruption: A Common Driver of Central Nervous System Diseases.

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.

Tumor-derived pericytes driven by EGFR mutations govern the vascular and immune microenvironment of gliomas.

Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype.

Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth